Related Experiment Video
Updated: Dec 30, 2025

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
[Mucopolysaccharidosis: A review]
M Michaud1, N Belmatoug2, F Catros1
1Centre de compétence des maladies lysosomales de l'adulte, hôpital Joseph-Ducuing, 31076 Toulouse, France; Médecine interne, hôpital Joseph-Ducuing, 31076 Toulouse, France.
Insights
Mucopolysaccharidoses are rare genetic disorders caused by enzyme deficiencies leading to mucopolysaccharide buildup. Early diagnosis and enzyme replacement therapy improve patient outcomes.
Area of Science:
- Biochemistry
- Genetics
- Pediatrics
Background:
- Mucopolysaccharidoses (MPS) are a group of rare lysosomal storage diseases.
- They result from the accumulation of glycosaminoglycans (mucopolysaccharides) due to enzyme deficiencies.
- Type 1 MPS is the most prevalent form, affecting approximately 0.69–1.66 per 100,000 live births.
Purpose of the Study:
- To highlight the clinical variability and common symptoms of mucopolysaccharidoses.
- To emphasize the importance of early recognition and diagnosis for effective patient management.
- To inform about diagnostic methods and available treatments, including enzyme replacement therapy.
Main Methods:
- Review of clinical manifestations and diagnostic approaches for mucopolysaccharidoses.
- Analysis of screening methods, including urinary glycosaminoglycan analysis.
- Confirmation of diagnosis through enzyme assays and genetic testing.
Main Results:
- Mucopolysaccharidoses present with a wide spectrum of severity, from in utero lethality to adult-onset forms.
- Common clinical features include short stature, facial dysmorphism, joint pain, skeletal abnormalities, hepatosplenomegaly, and carpal tunnel syndrome.
- Ocular, neurological, and cardiac complications can occur depending on the specific MPS type.
Conclusions:
- Prompt clinical suspicion and diagnosis of mucopolysaccharidoses are crucial for timely intervention.
- Diagnostic workup involves biochemical and genetic analyses.
- Enzyme replacement therapy is available for certain types, underscoring the importance of early detection for improved management and family screening.
Abstract:
Mucopolysaccharidosis are lysosomal storage diseases, secondary to the accumulation of mucopolysaccharides. Type 1 mucopolysaccharidosis is the most common form and affects between 0.69 and 1.66 newborns per 100,000. The severity of mucopolysaccharidosis is variable with lethal forms in utero and attenuated forms diagnosed in adults. The most common symptoms are short stature, facial dysmorphism, chronic articular pains that can mimic chronic inflammatory rheumatism, axial and peripheral bone involvement, hepatosplenomegaly and an early carpal tunnel. Depending on the type of mucopolysaccharidosis, corneal, cerebral or cardiac involvements are possible. Screening is based on the analysis of urinary glycosaminoglycans. The deficient enzyme assay and the gene analysis confirm the diagnosis. Mucopolysaccharidosis recognition is important for patient management and family screening. In addition, specific enzyme replacement therapy exists for certain types of mucopolysaccharidosis. Role of clinician is important to evoke and diagnose mucopolysaccharidosis.
Related Concept Videos
Lysosomal Hydrolases
Proteoglycans
Glycosaminoglycans
GAGS are found in the extracellular matrix of vertebrates, invertebrates, and bacteria. Due to their polar nature they attract water, and serve as excellent lubricants or shock absorbers in an animal body.
Hyaluronic...
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Cystic Fibrosis: Management
Sinus disease and chronic...

